|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1995-10-6
|
|
pubmed:abstractText |
To determine whether modifying the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) from full doses given every 3 weeks to one-third doses given weekly (chop) increases the received chemotherapy dose-intensity in elderly patients with advanced-stage intermediate-grade lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
2386-93
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7666098-Aged,
pubmed-meshheading:7666098-Aged, 80 and over,
pubmed-meshheading:7666098-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7666098-Chi-Square Distribution,
pubmed-meshheading:7666098-Cyclophosphamide,
pubmed-meshheading:7666098-Disease-Free Survival,
pubmed-meshheading:7666098-Doxorubicin,
pubmed-meshheading:7666098-Drug Administration Schedule,
pubmed-meshheading:7666098-Female,
pubmed-meshheading:7666098-Humans,
pubmed-meshheading:7666098-Life Tables,
pubmed-meshheading:7666098-Lymphoma, Non-Hodgkin,
pubmed-meshheading:7666098-Male,
pubmed-meshheading:7666098-Pilot Projects,
pubmed-meshheading:7666098-Prednisone,
pubmed-meshheading:7666098-Remission Induction,
pubmed-meshheading:7666098-Survival Rate,
pubmed-meshheading:7666098-Vincristine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Medicine, Pathology, McMaster University, Hamilton, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
